HiberCell develops therapeutic molecules aimed at preventing cancer relapse and metastasis by targeting stress biology and innate immunity. The company’s lead candidate, HC-5404-FU, is the first from its 'stress modulator' platform and reportedly has direct anti-tumor activity while reprogramming the immunosuppressive tumor microenvironment. HiberCell views cancer as a chronic disease and is focused on therapies that address relapse and metastasis. The company will use proceeds from its recent financings to support clinical development of these novel therapeutics. HiberCell is led by Co-Founder and CEO Alan Rigby, Ph.D. and is based in New York City. HiberCell develops therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers to prevent relapse and metastasis. The company is exclusively focused on DTC-directed drug discovery and development. At launch, Alan Rigby, Ph.D., will serve as president and chief scientific officer; Ari Nowacek, Ph.D., M.D., will serve as vice president of operations and business development; and Mark Mulvihill, Ph.D., will serve as vice president of chemistry and drug discovery. Its team comprises cancer scientists, venture capitalists and drug developers. HiberCell raised $60.75M in Series A financing to advance its therapeutic programs. The company has assembled a board and a scientific advisory board with academic and industry leaders to guide its programs.

Total raised

$158M

Funding rounds

3

Latest round

Debt Financing

Latest activity

May 2021